RealFeedApp FDA grants Fast Track status to Sironax's lead drug
Biotech Sironax presented three abstracts on drug SIR2501 at Neuroscience 2026. The medication blocks the SARM1 enzyme responsible for nerve damage during chemotherapy and in ALS.
- Field
- ageing and longevity
- What they did
- Biotech company Sironax presented drug SIR2501, which blocks the SARM1 enzyme responsible for nerve damage in chemotherapy and ALS. The drug received FDA Fast Track status and is featured in three scientific abstracts for the 2026 conference.
- Why it matters
- This could help patients who underwent chemotherapy avoid numbness and pain in their limbs, as well as treat other conditions associated with nerve damage.
#sarm1#chemotherapy#nerve damage#sironax#sir2501
